Sisomicin is the most predictably active aminoglycoside against gram-positive bacteria. Like most other aminoglycosides, Sisomicin is bactericidal for sensitive clinical isolates. The Minimum Bactericidal Concentrations (MBC) have been found to be equivalent or very close to the Minimum Inhibitory Concentrations (MIC). Like other aminoglycosides, most clinical isolates of Pseudomonas aeruginosa remain susceptible to sisomicin. Resistance to sisomicin may enzymatically or non-enzymatically be mediated. Sisomicin is inactivated by the same enzymes as gentamicin but it is active against many, not all, organisms that resist gentamicin by non-enzymatic mechanisms.
Some studies show that sisomicin has been effective in the treatment of infections that either had failed to respond to other drugs or were due to microorganisms resistant in vitro to other aminoglycosides.
^M. J. Weinstein, J. A. Marquez, R. T. Testa, G. H. Wagman, E. M. Oden, J. A. Waitz (Nov 1970). "Antibiotic 6640, a new Micromonospora-produced aminoglycoside antibiotic.". J. Antibiot.23 (11): 551–554. PMID5487129.
^ abWE Sanders Jr, CC Sanders. (Mar–Apr 1980). "Sisomicin: a review of eight years' experience.". Rev Infect Dis.2 (2): 182–195. PMID6994206.
^I Phillips, BA King, KP Shannon. (Mar 1978). "The mechanisms of resistance to aminoglycosides in the genus Pseudomonas.". J Antimicrob Chemother.4 (2): 121–129. PMID649532.
^ME Levison, D Kaye. (Mar 1979). "A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies.". Medicine (Baltimore).58 (2): 159–170. PMID431401.
^DG Maki, WA Craig, WA Agger. (Jun 1979). "A comparative clinical trial of sisomicin and gentamicin in major gram-negative infections.". Infection 7(Suppl. 3)5 (6): 298–300.